Iksuda Therapeutics Enters License Agreement With University of Goettingen to Develop a New Generation of Antibody Drug Conjugates

Christel Deskins

Iksuda licenses novel protein-alkylating, tumour-activated pro-drug payload series to develop ADCs with enhanced therapeutic index Development to focus on targets associated with haematological and solid tumours Iksuda Therapeutics (Iksuda), the developer of enhanced, new-generation of Antibody Drug Conjugates (ADCs), today announces it has executed its option to secure exclusive, worldwide […]